<DOC>
	<DOCNO>NCT02148601</DOCNO>
	<brief_summary>In recent past , deep change epidemiology C. difficile infection occur , rise frequency , severity , mortality . Both refractoriness infection standard therapy probability recurrence also increase , represent main clinical issue . Fecal microbiota transplantation ( FMT ) refer introduction liquid filtrate stool healthy donor gastrointestinal tract patient treatment specific disease . FMT show outstanding result treatment recurrent C. difficile infection . It perform various route : nasogastric nasojejunal tube , upper endoscopy , retention enema , colonoscopy . In recent systematic review study use FMT treatment recurrent C. difficile infection , Cammarota et al . observe low gastrointestinal route ( colonoscopy , enema ) lead achievement high eradication rate upper delivery ( gastroscopy , naso-gastric naso-jejunal tube ) ( 81-86 % vs 84-93 % , respectively ) . In randomized clinical trial , Van Nood et al . show efficacy FMT nasojejunal tube recurrent C. difficile infection . Up , data FMT low route come case series case report . The investigator ' aim compare efficacy colonoscopic FMT standard antibiotic therapy treatment C. difficile infection randomize clinical trial</brief_summary>
	<brief_title>Fecal Microbiota Transplantation Colonoscopy Recurrent C. Difficile Infection</brief_title>
	<detailed_description>In recent past , deep change epidemiology C. difficile infection occur , rise frequency , severity , mortality . Both refractoriness infection standard therapy probability recurrence also increase , represent main clinical issue . Fecal microbiota transplantation ( FMT ) refer introduction liquid filtrate stool healthy donor gastrointestinal tract patient treatment specific disease . FMT show outstanding result treatment recurrent C. difficile infection . It perform various route : nasogastric nasojejunal tube , upper endoscopy , retention enema , colonoscopy . In recent systematic review study use FMT treatment recurrent C. difficile infection , Cammarota et al . observe low gastrointestinal route ( colonoscopy , enema ) lead achievement high eradication rate upper delivery ( gastroscopy , naso-gastric naso-jejunal tube ) ( 81-86 % vs 84-93 % , respectively ) . In randomized clinical trial , Van Nood et al . show efficacy FMT nasojejunal tube recurrent C. difficile infection . Up , data FMT low route come case series case report . The investigator ' aim compare efficacy colonoscopic FMT standard antibiotic therapy treatment C. difficile infection open-label randomized clinical trial The investigator ' trial confirm clinical result obtain Van Nood et al . use colonoscopy approach . The investigator ' study open-label randomize controlled trial , enrol patient recurrent C. difficile infection , candidate antibiotic treatment accordance guideline . Recurrent C. difficile infection mean reappearance clinical symptom positivity C. difficile toxin test within 8 week end previous therapy . Patients ' stool screen detection parasite enteric bacterial pathogen exclude infective pathogen . Patients severe clinical feature ( sepsis , severe dehydration , major co-morbidities ) , former colectomy , high-risk endoscopic complication , inflammatory bowel disease ( IBD ) , irritable bowel syndrome ( IBS ) , viral hepatitis , AIDS syphilis exclude . Patients instruct invited signal recurrent symptom diarrhea treatment . Monthly clinical lab check perform period six month treatment . Treatment procedure : All patient start therapy vancomycin four day stratification , random allocation ( 1 1 ) one two treatment scheme : 1 ) FMT , infusion cecum - biopsy channel - 60-120 gr ( depend production ) donate feces , obtain donor within 6 hour transplantation , manually homogenize 100/200 ml physiological solution ; 2 ) standard vancomycin-based therapy accord international recommendation . Colonoscopy perform expert endoscopist , mucosal biopsy ( possible ) histology examination . Patients allocate FMT arm undergo preparation colonoscopy ( four liter solution saline laxative ) . All patient instruct hygiene rule follow patient 's domicile avoid re-infections home . Stool donor preferably patient 's relative intimate , must take antibiotic last 6 month , present significant intestinal symptom intestinal disease must result negative serum screen viral hepatitis , AIDS syphilis . Their stool test C. difficile , enteric bacteria , intestinal protozoa helminthes pathogen .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<criteria>Symptomatic recurrent C. difficile infection identify positivity C. difficile toxin stool ( ELISA ) Possibility undergo standard antimicrobial therapy recurrent C. difficile infection Approval inform consent Possibility undergo protocol diagnostic therapeutic procedure Stool negativity parasites Stool negativity Salmonella spp. , Shigella spp. , Yersinia enterocolitica , Campylobacter , Streptococcus agalactiae , Staphylococcus aureus , enteropathogenic Escherichia coli microorganism except C. difficile Blood negativity : Hepatitis A virusImmunoglobulin M , HBsAg , AntiHepatitis C Virus , AntiHuman Immunodeficiency Virus12 , venereal disease reaction level ( VDRL ) . Subjects &lt; 18 year old Main comorbidities Prior colectomy Negativity C. difficile toxin stool High risk postcolonoscopy complication Other main gastrointestinal disease ( e . Crohn 's disease ulcerative colitis ) Stool positivity parasites Stool positivity Salmonella spp. , Shigella spp. , Yersinia enterocolitica , Campylobacter , Streptococcus agalactiae , Staphylococcus aureus , enteropathogenic Escherichia coli microorganism except C. difficile Blood positivity : Hepatitis A virusImmunoglobulin M , HBsAg , AntiHepatitis C Virus , AntiHuman Immunodeficiency Virus12 , venereal disease reaction level ( VDRL ) . Pregnancy breastfeed . Inability follow protocol procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Fecal microbiota transplantation</keyword>
	<keyword>Recurrent C. difficile infection</keyword>
	<keyword>Colonoscopy</keyword>
	<keyword>Randomized clinical trial</keyword>
</DOC>